Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
64
62
31
28
28
13
Research & Development
384
281
210
142
121
45
Operating Expenses
449
343
242
170
150
58
Other Non Operating Income (Expenses)
-1
0
-1
0
0
0
Pretax Income
-423
-317
-235
-168
-149
-59
Income Tax Expense
--
--
--
--
--
--
Net Income
-423
-317
-235
-168
-149
-59
Net Income Growth
44%
35%
40%
13%
153%
321%
Shares Outstanding (Diluted)
141.81
94.14
59.68
51.98
50.9
45.08
Shares Change (YoY)
41%
57.99%
15%
2%
13%
3%
EPS (Diluted)
-2.98
-3.37
-3.95
-3.23
-2.93
-1.32
EPS Growth
2%
-15%
22%
10%
122%
288%
Free Cash Flow
-397
-294
-188
-156
-123
-47
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
-448
-342
-241
-169
-149
-58
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
1
1
1
1
1
0
EBIT
-449
-343
-242
-170
-150
-58
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
--
--
--
--
--
--
Follow-Up Questions
What are Dyne Therapeutics Inc's key financial statements?
What are the key financial ratios for DYN?
How is Dyne Therapeutics Inc's revenue broken down by segment or geography?
Is Dyne Therapeutics Inc profitable?
Does Dyne Therapeutics Inc have any liabilities?
How many outstanding shares for Dyne Therapeutics Inc?
Key Stats
Prev.Close
$17.14
Open
$17.07
Day's Range
$16.27 - $17.07
52 week range
$6.36 - $25
Volume
600.9K
Avg.Volume
2.5M
EPS (TTM)
-3.66
Dividend yield
--
Market Cap
$2.3B
What is DYN?
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 240 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.